XML 23 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity (Tables)
9 Months Ended
Oct. 31, 2019
Stockholders' equity  
Schedule of nonvested share activity
    Number of shares awarded total  
    Minimum     Target     Maximum     Cap  
Employees     35,863       53,796       71,728       86,125  
Non-employee Directors     14,414       21,622       28,829       34,595  
Total     50,277       75,418       100,557       120,720  

 

    Value at grant date (numbers below are rounded to the nearest $100)  
    Minimum     Target     Maximum     Cap  
Employees   $ 497,600     $ 746,400     $ 995,200     $ 1,194,900  
Non-employee Directors     200,000       300,000       400,000       480,000  
Total   $ 697,600     $ 1,046,400     $ 1,395,200     $ 1,674,900  

 

Schedule of share-based compensation
    Three Months Ended     Nine Months Ended  
    October 31,     October 31  
    2019     2018     2019     2018  
2017 Plan   $ (345 )   $ 189     $ (596 )   $ 491  
Total stock-based compensation   $ (345 )   $ 189     $ (596 )   $ 491  
Schedule of restricted stock units award activity

Shares issued under

2017 Stock Plan

  Outstanding Unvested Grants at Maximum at Beginning of FY20    

Granted during

FY20

    Becoming Vested during FY20    

Forfeited during

FY20

   

Outstanding Unvested Grants at Maximum at End of

October 31, 2019

 
Restricted stock grants – employees     84,126       -----       -----       12,397       71,729  
Restricted stock grants – non-employee directors     28,829       -----       -----       -----       28,829  
Retainer in stock – non-employee directors     25,044       7,292       2,675       -----       29,661  
  Total restricted stock     137,999       7,292       2,675       12,397       130,219  
                                         
Weighted average grant date fair value   $ 13.77     $ 11.63     $ 15.85     $ 13.87     $ 13.66  
Schedule of stock option activity

Stock Options

  Number of Shares     Weighted Average Exercise Price per Share     Weighted Average Remaining Contractual Term (in years)     Aggregate Intrinsic Value  
Outstanding at July 31, 2019     -----     $ -----       -----     $ -----  
Granted during the quarter ended October 31, 2019     24,900     $ 11.17       -----       -----  
Outstanding at October 31, 2019     24,900     $ 11.17       9.79       -----  
Exercisable at October 31, 2019     -----     $ -----       -----     $ -----  
Assumptions used to calculate the fair value of the options granted
    FY20  
       
Expected volatility     53 %
Expected life in years     10  
Expected dividend yield     0.00 %
Risk-free interest rate     1.65 %